title: Psoriatic arthritis.
abstract: Psoriatic arthritis exhibits specific characteristics that create challenges for physicians attempting to manage the disease. Active research has produced new knowledge in the fields of epidemiology, diagnostic criteria, evaluation tools, outcome prediction, and treatment. Biotherapies have been introduced for psoriatic arthritis, creating a need for a reappraisal of evaluation tools, outcome prediction, and parameters reflecting treatment effects. TNF-alpha antagonists constitute a breakthrough in the management of psoriatic arthritis. Similar to rheumatoid arthritis and ankylosing spondylitis, psoriatic arthritis is entering a new era of evaluation and treatment.
authors.affiliation: EA 3853 Immuno-Pharmaco-Génétics of Therapeutic Antibodies (IPGA), and Rheumatology Department, Trousseau Teaching Hospital, François Rabelais University, 37044 Tours cedex 9, France. goupille@med.univ-tours.fr
authors.forename: Philippe
authors.initials: P
authors.lastname: Goupille
mesh_terms: D000068879:Adalimumab; D000894:Anti-Inflammatory Agents, Non-Steroidal / Q000627:therapeutic use; D000911:Antibodies, Monoclonal / Q000627:therapeutic use; D061067:Antibodies, Monoclonal, Humanized; D018501:Antirheumatic Agents / Q000627:therapeutic use; D015535:Arthritis, Psoriatic / Q000175:diagnosis / Q000188:drug therapy*; D000068800:Etanercept; D006801:Humans; D007074:Immunoglobulin G / Q000627:therapeutic use; D007155:Immunologic Factors / Q000627:therapeutic use; D000069285:Infliximab; D007555:Isoxazoles / Q000627:therapeutic use; D000077339:Leflunomide; D018124:Receptors, Tumor Necrosis Factor / Q000627:therapeutic use; D014409:Tumor Necrosis Factor-alpha / Q000037:antagonists & inhibitors*
chemical_list: D000894:Anti-Inflammatory Agents, Non-Steroidal; D000911:Antibodies, Monoclonal; D061067:Antibodies, Monoclonal, Humanized; D018501:Antirheumatic Agents; D007074:Immunoglobulin G; D007155:Immunologic Factors; D007555:Isoxazoles; D018124:Receptors, Tumor Necrosis Factor; D014409:Tumor Necrosis Factor-alpha; D000069285:Infliximab; D000068879:Adalimumab; D000077339:Leflunomide; D000068800:Etanercept